Mirae Asset Global Etfs Holdings Ltd. Verve Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 86,613 shares of VERV stock, worth $964,002. This represents 0.0% of its overall portfolio holdings.
Number of Shares
86,613
Previous 140,727
38.45%
Holding current value
$964,002
Previous $643,000
51.17%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding VERV
# of Institutions
195Shares Held
72.2MCall Options Held
452KPut Options Held
2.96M-
Alphabet Inc. Mountain View, CA12.2MShares$135 Million8.86% of portfolio
-
Pentwater Capital Management LP Naples, FL6.72MShares$74.8 Million0.5% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$73.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.19MShares$46.7 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4.1MShares$45.6 Million6.45% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $667M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...